Using brain stimulation to improve symptoms in patients with Multiple System Atrophy - Cerebellar Variant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of anodal transcranial direct current stimulation (tDCS) in patients with Multiple System Atrophy - Cerebellar Variant (MSA-C). It is designed as a double-blind, randomized, sham-controlled trial with two independent arms, where participants will receive either active or sham stimulation over a period of five consecutive days. The study aims to assess the impact of tDCS on cerebellar symptoms and overall quality of life for patients suffering from this progressive neurodegenerative disease. A total of 30 patients will be recruited, with each participant receiving both types of stimulation in a crossover design.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Multiple system atrophy cerebellar variant according with the Movemente Disorder Society criteria (Wenning et al 2022)
* Ability to walk either indipendently or with a minimum support

Exclusion Criteria:

* Presence of electrical stimulators (for example, pacemaker, Deep Brain Stimulation, DBS)
* Difficult in understanding Italian language
* Presence of severe sensory deficits (for example, visual or hearing impairments)
* History of drug abuse
* History of severe psychiatric disorders
* History of transient ischemic attacks
* Cortical or sub-cortical vascular lesions
* Seizures or severe heart problems and previous neurosurgical operations
* Pregnancy

Where it's running

• Centro per le Malattie Neurodegenerative (CEMAND) Dipartimento di Medicina e chirurgia, Sezione Neuroscienze, Università di Salerno
  Salerno, Sa, Italy Recruiting

Study contacts

• Study coordinator: Roberto Erro MD, PhD
• Email: rerro@unisa.it
• Phone: 089673073

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ALT001 safety and early effectiveness test in MSA-C patients

  A small, open-label, randomized study will test whether ALT001 is safe and potentially helpful for adults with MSA-C who have had symptoms for a short time.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07514923

• Genetic program for Progressive Supranuclear Palsy and related conditions

  This study is collecting DNA from adults with Progressive Supranuclear Palsy and similar conditions to see how genetics might help improve diagnosis and care for patients.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06647641

• Home-based cardiac telerehabilitation for adults with chronic heart failure

  This program will test whether a home-based telerehabilitation course using wearable sensors and remote supervision helps adults with chronic heart failure improve their exercise capacity compared with standard in-hospital rehabilitation.

  Recruiting University of Salerno · Salerno · NCT07023536

• AI-driven wearable monitoring for chronic heart failure

  This project will try an AI-driven wearable and mini‑invasive device to see if continuous home monitoring reduces hospital visits and improves health for adults with chronic heart failure.

  Recruiting University of Salerno · Salerno · NCT06909682

• Evaluating outcomes of transcatheter aortic valve replacement for severe low flow, low gradient aortic stenosis

  This study is testing how well transcatheter aortic valve replacement works for people with severe low flow, low gradient aortic stenosis and tracking their health outcomes over time.

  Recruiting University of Salerno · Salerno · NCT06589063

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.